The EU did a Brexit trade deal with the pharma industry: it tried to lock in a perceived short-term price advantage at the expense of everything else. Instead of prioritising the speed and security of supplies at any price, the EU prioritised the price. The EU paid 24% less for the Pfizer vaccine than the US, for example. For the Oxford/AstraZeneca vaccine, the price gap is 45%. The UK almost certainly paid a lot more. It is no wonder that the manufacturers are prioritising orders on a first-come, first-serve basis, and from countries that pay the full price. The price difference is macroeconomically irrelevant. But if vaccine shortages lead to longer lockdowns, the indirect effect of that short-sighted policy will be massive.
Related Articles

Economics
Guntram B. Wolff: Inflation!? Germany, the euro area and the European Central Bank
A much needed no-nonsense assessment of inflation risks in the euro area and in Germany Read here

Geopolitics
Jeremy Corbyn: ‘Look at Gaza — Our Political Class Only Pays Lip Service to Human Rights’
Today marks 75 years of the Universal Declaration of Human Rights. But, as Gaza shows, it is being buried under the rubble along with the human beings whose rights it was written to protect, writes […]

EU politics
German Foreign Policy: German Combat Exercises in Southeast Asia
German Bundeswehr expands combat exercises in the Asia-Pacific region – at a time when the USA conducts record maneuvers in Southeast Asia and China seeks to secure military influence. Read HERE
Be the first to comment